TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31167889

Group type: EXPERIMENTAL
Intervention: Metformin plus Rosiglitazone (M + R)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Metformin plus Lifestyle (M + L)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Metformin (M)
Number of subjects: 626
Study: 27632886

Group type: EXPERIMENTAL
Intervention: Euhydrated (EU)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypohydrated (HY)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison of EU and HY trials
Number of subjects: 9
Study: 25409256

Group type: EXPERIMENTAL
Intervention: Acute MRI
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (2 weeks cast immobilization)
Number of subjects: 124
Study: 23406619

Group type: COMPARATOR
Intervention: 80%C
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 80%Caps
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 80%P
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 80%PCaps
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 80%Caps, 80%P, 80%PCaps
Number of subjects: 24
Study: 21195575

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Self‐help program (CBS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting List Control group (WLC)
Number of subjects: 32
Study: 19522133

Group type: EXPERIMENTAL
Intervention: Supported education services (experimental group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 38
Study: 16712621

Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Expectations in the High group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neuropathic pain quality
Number of subjects: 60
Study: 14979749

Group type: EXPERIMENTAL
Intervention: Valuation by feeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valuation by calculation
Number of subjects: 0
Study: 11172507

Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 0.25% bupivacaine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 0.5% bupivacaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 12
Study: 9516191

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage (C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo beverage (P)
Number of subjects: 10
Study: 7995776

Group type: EXPERIMENTAL
Intervention: Knowledge-of-Results (KR) group
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-Knowledge-of-Results (NKR) group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Random-Knowledge-of-Results (RKR) group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Knowledge-of-Results (KR) group (aware Ss)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Knowledge-of-Results (KR) group (unaware Ss)
Number of subjects: 48
Study: 3421201

Group type: EXPERIMENTAL
Intervention: 2000 IU (50 micrograms) of vitamin D/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 IU (25 micrograms) of vitamin D/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 0
Study: 30476957

Group type: EXPERIMENTAL
Intervention: Lp(a) levels
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OxPL‐apoB levels
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OxPL‐apo(a) levels
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Lp(a) levels in younger patients
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OxPL‐apoB levels in younger patients
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OxPL‐apo(a) levels in younger patients
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Comprehensive multivariable adjustment
Number of subjects: 220
Study: 26185392

Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids (PPH)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (conventional surgery)
Number of subjects: 108
Study: 23518003

Group type: EXPERIMENTAL
Intervention: In-surgery bleaching with light activated 25% hydrogen peroxide gel followed by 2 weeks at home, night time bleaching with 10% carbamide peroxide gel in a customised bleaching tray.
Number of subjects: 22

Group type: COMPARATOR
Intervention: In-surgery bleaching with 25% hydrogen peroxide without light activation followed by 2 weeks at home, night time bleaching with 10% carbamide peroxide gel in a customised bleaching tray.
Number of subjects: 22
Study: 21502449

Group type: EXPERIMENTAL
Intervention: Alcohol consumption until intoxicated (study 1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Abstaining from alcohol (study 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Free alcohol consumption until intoxicated (study 2)
Number of subjects: 24
Study: 19628185

Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 2060
Study: 16428497

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m(2)) with aspirin (325 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m(2)) with ibuprofen (400 mg; 2 x 200 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pemetrexed alone
Number of subjects: 54
Study: 15447822

Group type: EXPERIMENTAL
Intervention: Gln + rhGH
Number of subjects: 60

Group type: COMPARATOR
Intervention: C
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gln
Number of subjects: 60
Study: 11522769

Group type: EXPERIMENTAL
Intervention: Natural-language-based entry system
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard graphical user interface
Number of subjects: 16
Study: 9237092

Group type: EXPERIMENTAL
Intervention: Guided Imagery and Music (GIM) therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 28
Study: 7954026

Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide dinitrate (ISDN) 40 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2901668

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (400 mg per kilogram of body weight) every three weeks for one year
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 29278279

Group type: EXPERIMENTAL
Intervention: Camicinal 50 mg once-daily
Number of subjects: 58
Study: 27421242

Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 5 mg
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 10 mg
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 20 mg
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 40 mg
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OLM) 20 mg
Number of subjects: 555
Study: 24103157

Group type: EXPERIMENTAL
Intervention: Thin tissues (Group A)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Thin tissues thickened with allogenic membrane (Group B)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Thick tissues (Group C)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 103

Group type: COMPARATOR
Intervention: Comparison between Group A and Group C
Number of subjects: 103

Group type: COMPARATOR
Intervention: Comparison between Group B and Group C
Number of subjects: 103
Study: 24569327

Group type: EXPERIMENTAL
Intervention: Injection of botulinum toxin into the pyloric sphincter muscle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pyloroplasty
Number of subjects: 60
Study: 16331103

Group type: EXPERIMENTAL
Intervention: Day 1 resting blood pressure measurements taken in a non-medical setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic resting blood pressure measurements taken before seeing the physician
Number of subjects: 0
Study: 12800457

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg/HCTZ 12.5 mg
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/HCTZ 12.5 mg
Number of subjects: 597
Study: 10569261

Group type: EXPERIMENTAL
Intervention: Abduction orthosis treatment initiated at approximately 4 months of age in 6 cases with persisting dysplasia
Number of subjects: 93

Group type: COMPARATOR
Intervention: No treatment (87 children)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Abduction orthosis treatment
Number of subjects: 93
Study: 7556835

Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone
Number of subjects: 200

Group type: COMPARATOR
Intervention: 1.5 g cefuroxime + 0.5 g metronidazole
Number of subjects: 200
Study: 1974503

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 107
Study: 7296744

Group type: EXPERIMENTAL
Intervention: High intensity interval training (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no exercise, n = 8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Detraining after 2 weeks
Number of subjects: 17
Study: 29383480

Group type: EXPERIMENTAL
Intervention: BoNT-A prostatic injection (200 UI)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Optimized medical therapy
Number of subjects: 127
Study: 29083439

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (DHA 800 mg and EPA 225 mg daily for 3 years)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo (identical capsules comprising liquid paraffin oil)
Number of subjects: 183
Study: 26266835

Group type: EXPERIMENTAL
Intervention: Transparent perfluorodecalin (PFD) infused patch with Q-switched Alexandrite laser (755 nm)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control side treated with one pass of standard Q-switched Alexandrite laser (755 nm)
Number of subjects: 17
Study: 24185285

Group type: EXPERIMENTAL
Intervention: MIAU curriculum (Mental Illness Among Us)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Non-participants (Control)
Number of subjects: 250
Study: 21386089

Group type: EXPERIMENTAL
Intervention: NEVO sirolimus-eluting stent (NEVO SES)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TAXUS Liberté paclitaxel-eluting stent (TAXUS Liberté PES)
Number of subjects: 100
Study: 18192468

Group type: EXPERIMENTAL
Intervention: Tris-acryl gelatin microspheres
Number of subjects: 53

Group type: COMPARATOR
Intervention: PVA microspheres
Number of subjects: 53
Study: 15845718

Group type: EXPERIMENTAL
Intervention: Normal saline (NS; 0.9% NaCl)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 51
Study: 12875455

Group type: EXPERIMENTAL
Intervention: Vertical conjunctival bridge flap technique
Number of subjects: 500

Group type: COMPARATOR
Intervention: Bare sclera technique
Number of subjects: 500
Study: 10540136

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (group 1; n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No thoracic epidural analgesia (group 2; n = 10)
Number of subjects: 20
Study: 8862087

Group type: EXPERIMENTAL
Intervention: Unstructured cases (late rotation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Structured cases (late rotation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unstructured cases (early rotation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Structured cases (early rotation)
Number of subjects: 0
Study: 1746458

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nifedipine 20 mg four times daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg once daily (follow-up)
Number of subjects: 30
Study: 6755255

Group type: EXPERIMENTAL
Intervention: Less intense anticoagulant therapy (mean prothrombin time of 26.9 seconds, Simplastin time 15 seconds)
Number of subjects: 96

Group type: COMPARATOR
Intervention: More intense anticoagulant therapy (mean Simplastin time of 19.4 seconds, prothrombin time 41 seconds)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups (less intense and more intense therapy)
Number of subjects: 96
Study: 31996555

Group type: EXPERIMENTAL
Intervention: Suture-type catheter
Number of subjects: 70

Group type: COMPARATOR
Intervention: Through-the-needle catheter
Number of subjects: 70
Study: 30513231

Group type: EXPERIMENTAL
Intervention: Stimulant and non-stimulant treatments for ADHD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADHD-specific drugs combined with SUD treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological treatments for ADHD
Number of subjects: 0
Study: 28041770

Group type: EXPERIMENTAL
Intervention: Direct Expert Feedback (DEF)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Unsupervised Video Feedback (UVF)
Number of subjects: 71
Study: 25435406

Group type: EXPERIMENTAL
Intervention: Endotracheal tube (ET)‐assisted technique from the mouth
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional technique from the nostril (control group)
Number of subjects: 56
Study: 24997499

Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=24)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care (n=25)
Number of subjects: 49
Study: 22413938

Group type: EXPERIMENTAL
Intervention: etravirine 200 mg bid
Number of subjects: 1203

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1203
Study: 19589009

Group type: EXPERIMENTAL
Intervention: Educational intervention for patients and PCPs (face-to-face education for PCPs, letters and automated calls for patients)
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Educational intervention for patients and PCPs
Number of subjects: 1867
Study: 17334256

Group type: EXPERIMENTAL
Intervention: Silver-impregnated catheters
Number of subjects: 577

Group type: COMPARATOR
Intervention: Standard catheters
Number of subjects: 577
Study: 15213060

Group type: EXPERIMENTAL
Intervention: Hypertonic NaCl solution infusion (855 mmol/l) followed by free access to water
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 16
Study: 11579072

Group type: EXPERIMENTAL
Intervention: Exercise intervention (twice weekly Osteofit classes for 10 weeks)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 11189212

Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Number of subjects: 124

Group type: COMPARATOR
Intervention: ticarcillin/clavulanic acid
Number of subjects: 124
Study: 7653793

Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia (1% end‐tidal isoflurane and nitrous oxide in oxygen)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propofol/alfentanil anaesthesia (propofol 2 mg/kg, alfentanil 15 micrograms/kg, maintained by infusion of propofol and alfentanil)
Number of subjects: 17
Study: 2744287

Group type: EXPERIMENTAL
Intervention: Checklist intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: No checklist (Control)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Both groups (Checklist and Control)
Number of subjects: 114
Study: 903059

Group type: EXPERIMENTAL
Intervention: 100mg Benzbromarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50mg Benzbromarone
Number of subjects: 0
Study: 30972484

Group type: EXPERIMENTAL
Intervention: Herring (HER)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Salmon (SAL)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cod (COD)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Milk (CAS, a casein-whey mixture as positive control)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Milk (CAS)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 93
Study: 31622142

Group type: EXPERIMENTAL
Intervention: Point-of-care informational interventions (flyers and posters encouraging vaccination) during a 3-month intervention period.
Number of subjects: 8837

Group type: COMPARATOR
Intervention: Usual care during a 4-month control period.
Number of subjects: 8837
Study: 29316016

Group type: EXPERIMENTAL
Intervention: 1.4% zinc sulfate shower gel (n=20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (n=20)
Number of subjects: 30
Study: 25922978

Group type: COMPARATOR
Intervention: 30 ml bupivacaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: 30 ml bupivacaine with 100 μg of fentanyl
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 30 ml bupivacaine with 100 ng naloxone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 30 ml bupivacaine with 100 μg of fentanyl and 100 ng naloxone
Number of subjects: 68
Study: 23102518

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) standard-dose for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (healthy controls matched by age)
Number of subjects: 58
Study: 22030144

Group type: EXPERIMENTAL
Intervention: Foley catheter (30 mL)
Number of subjects: 824

Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2 gel
Number of subjects: 824
Study: 20183354

Group type: EXPERIMENTAL
Intervention: In-person formative SP examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Web-based formative SP examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formats (in-person and web-based)
Number of subjects: 0
Study: 17053181

Group type: EXPERIMENTAL
Intervention: sNMES (surface neuromuscular electrical stimulation)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: sNMES
Number of subjects: 176
Study: 12722173

Group type: EXPERIMENTAL
Intervention: Spa therapy for 3 weeks during a 20-week spa period
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-spa period (control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 31
Study: 11712398

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 0
Study: 9189963

Group type: EXPERIMENTAL
Intervention: Midazolam (0.75 mg.kg‐1 by mouth)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (5 ml of water)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study: 1552106

Group type: EXPERIMENTAL
Intervention: rt-PA (100 mg with an initial bolus dose of 15 mg followed by an infusion of 50 mg over 30 min and 35 mg over 60 min)
Number of subjects: 421

Group type: COMPARATOR
Intervention: APSAC
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 421
Study: 3910726

Group type: EXPERIMENTAL
Intervention: H142 at 1.0 mg/kg per h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: H142 at 2.5 mg/kg per h
Number of subjects: 9

Group type: COMPARATOR
Intervention: 5% dextrose (control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: H142 (1.0 and 2.5 mg/kg per h)
Number of subjects: 9
Study: 31162856

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening, 5 annual rounds
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Control arm (X-ray screening)
Number of subjects: 4052
Study: 29078037

Group type: COMPARATOR
Intervention: Single-dose IV bococizumab (0.3, 1, 3, 6, 12, or 18 mg/kg)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Single-dose IV bococizumab (0.5 or 4 mg/kg) added to ongoing atorvastatin 40 mg/day
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Single-dose fixed SC bococizumab (100 or 200 mg) or IV bococizumab (200 mg)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Weekly IV bococizumab (0.25, 0.5, 1, or 1.5 mg/kg)
Number of subjects: 188
Study: 27669019

Group type: EXPERIMENTAL
Intervention: DECEPTION group (unaware of SS literature)
Number of subjects: 28

Group type: COMPARATOR
Intervention: BIASED group (aware of SS literature)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28

Group type: COMPARATOR
Intervention: BIASED group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DECEPTION group
Number of subjects: 28
Study: 24786469

Group type: EXPERIMENTAL
Intervention: Heated, humidified, high‐flow nasal cannula (HHHFNC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal continuous positive airways pressure (NCPAP)
Number of subjects: 20
Study: 22182053

Group type: EXPERIMENTAL
Intervention: WBI-1001 0.5%
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: WBI-1001 1.0%
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 20889939

Group type: COMPARATOR
Intervention: Levobupivacaine + Saline (Group L)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine + Dexmedetomidine (Group LD)
Number of subjects: 60
Study: 17939171

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available solid oral dosage pharmaceutical formulations (tablets)
Number of subjects: 0
Study: 16099718

Group type: EXPERIMENTAL
Intervention: 4.5 g sodium oxybate nightly for 8 weeks
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 6 g sodium oxybate nightly for 8 weeks
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 9 g sodium oxybate nightly for 8 weeks
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 12384207

Group type: EXPERIMENTAL
Intervention: Female condom (FC) use
Number of subjects: 330
Study: 10443596

Group type: EXPERIMENTAL
Intervention: Nitecapone (cardioplegia supplemented with nitecapone)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (crystalloid cardioplegia)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitecapone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 8578179

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 6 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 2364570

Group type: EXPERIMENTAL
Intervention: EMLA cream applied 1 hour prior to infiltration
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo cream applied 1 hour prior to infiltration
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: EMLA applied to one lesion and placebo to another lesion
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo applied to one lesion and EMLA to another lesion
Number of subjects: 2
Study: 383276

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 IV on day 1 plus DTIC 200 mg/m2 IV days 1 through 5
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cyclophosphamide 600 mg/m2 IV on day 1 plus DTIC 200 mg/m2 IV days 1 through 5 plus C. parvum 5 mg/m2 IV on day 8 and day 15
Number of subjects: 120